Ensysce Biosciences (ENSC) revenue and earnings history
Ensysce Biosciences reported revenue of $5.07M for fiscal 2025 (year ended Dec 31, 2025), −2.8% on the year before.
Over 5 years, from fiscal 2020 to fiscal 2025, revenue grew at a compound rate of +5.2% a year.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $5.07M−2.8% | −$10.2M | — | −$7.81M | $124K | −$7.93M | $177K | — | — | $4.31M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Ensysce Biosciences (ENSC) on OQRO.
Common questions
What was Ensysce Biosciences's revenue in fiscal 2025?
$5.07M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 30, 2026. That is −2.8% on fiscal 2024 ($5.21M).
How fast has Ensysce Biosciences's revenue grown?
From $3.93M in fiscal 2020 to $5.07M in fiscal 2025: a compound annual growth rate of +5.2% over 5 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Ensysce Biosciences tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
